Form 4: Veradigm SVP General Counsel Awarded Significant Restricted Stock Units

Veradigm Inc.'s SVP General Counsel, Tejal Vakharia, was granted 69,768 Restricted Stock Units on June 2, 2025, under the company's 2024 Stock Incentive Plan.

Summary

• Tejal Vakharia, SVP General Counsel of Veradigm Inc. (MDRX), was granted 69,768 Restricted Stock Units (RSUs) on June 2, 2025.
• The RSUs were awarded under the Veradigm, Inc. Amended and Restated 2024 Stock Incentive Plan.
• The grant vests 50% on each of the first two anniversaries of the grant date (June 2, 2025).
• Following this transaction, Ms. Vakharia beneficially owns a total of 387,476 shares of Veradigm common stock.
• The stated price per RSU for this acquisition was $4.3.

Sentiment

Score: 7

Explanation: The document indicates a routine executive compensation event, which is generally positive for aligning management interests with shareholders and retaining key talent. It does not suggest any negative operational or financial issues.

Positives

• The grant of Restricted Stock Units aligns the interests of a key executive, Tejal Vakharia, with those of shareholders, promoting long-term value creation.
• This equity award serves as a retention mechanism for senior talent within Veradigm Inc., ensuring continuity in leadership.

Future Outlook

The grant of Restricted Stock Units implies future share ownership for the SVP General Counsel, aligning her long-term incentives with the company's performance as the units vest over the next two years.

Management Comments

• The grant of Restricted Stock Units to Tejal Vakharia, SVP General Counsel, reflects the company's ongoing executive compensation strategy under the Veradigm, Inc. Amended and Restated 2024 Stock Incentive Plan.

Industry Context

This RSU grant is a standard practice in executive compensation across the healthcare technology and software industries, aiming to attract, retain, and incentivize key leadership by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) with a multi-year vesting schedule is a common and widely accepted form of executive compensation in the technology and healthcare sectors, comparable to practices at companies like Cerner (now Oracle Health) or Epic Systems (though private, similar equity incentives are common in the broader industry).
• The vesting schedule of 50% on each of the first two anniversaries is a typical short-to-medium term vesting structure designed to encourage executive retention and performance over a defined period.

Stakeholder Impact

• Shareholders: The RSU grant aligns the interests of a key executive with shareholders, potentially leading to better long-term performance and value creation.
• Employees: This type of executive compensation can signal stability and a commitment to retaining top talent, which can positively influence employee morale.
• Management: The grant provides a significant equity incentive for the SVP General Counsel, motivating her to contribute to the company's success.

Next Steps

• Vesting of 50% of the granted Restricted Stock Units on June 2, 2026.
• Vesting of the remaining 50% of the granted Restricted Stock Units on June 2, 2027.

Key Dates

Recommendation

Keywords

Veradigm, MDRX, Restricted Stock Units, RSU, Stock Incentive Plan, Executive Compensation, Tejal Vakharia, Insider Transaction, Form 4, Equity Grant